Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05327322 · ClinicalTrials.gov registry record · NA
Functional Outcomes From Diets in Multiple Sclerosis
A NA study of Relapsing Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT05327322: Recruiting NA study of Relapsing Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis, sponsored by University of Alabama at Birmingham.
NCT05327322 is a NA study of Relapsing Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 100 participants, below the 199-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05327322, a NA study of Relapsing Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS). The investigators will also explore the how the diet interventions impact inflammation, immunity, and metabolic biomarkers.
Primary Outcome
The MSFC includes a timed T25FW, 9-hole peg test (9HPT), and the Paced Auditory Serial Addition Test (PASAT).
Conditions Studied
Interventions
- BEHAVIORAL Glycemic load
- BEHAVIORAL Calorie restriction
- BEHAVIORAL Behavioral support
Study Locations (2)
Alabama
- University of Alabama at Birmingham - Birmingham
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2026-11-01 |
| Phase | NA |
What NCT05327322 shows while recruiting
NCT05327322 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 199-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Glycemic load is the first listed.
NCT05327322 reports a single indexed study location in Alabama, Missouri.
Frequently Asked Questions
What is clinical trial NCT05327322 about?
NCT05327322 is a clinical study titled "Functional Outcomes From Diets in Multiple Sclerosis". The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS). The investigators will also explore the how the diet interventions impact in...
What is the current status of trial NCT05327322?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2023-03-20. Estimated completion is 2026-11-01.
What conditions does trial NCT05327322 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT05327322?
The interventions under investigation include: Glycemic load (BEHAVIORAL), Calorie restriction (BEHAVIORAL), Behavioral support (BEHAVIORAL).
Who is sponsoring clinical trial NCT05327322?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05327322 being conducted?
This trial has 2 study locations across Alabama, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05327322's enrollment target sits among peer trials
100 12th of 25 higher than 14 of 25 other Relapsing Remitting Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
-
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
COMPLETED · NA
-
Development of a Motivational Intervention to Improve Treatment Adherence in MS
COMPLETED · NA
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI